September 15th, 2021Rare Disease Innovation and Data Sharing Accelerated by New RDCA-DAP Program TUCSON, Ariz. and WASHINGTON, September 15, 2021 — The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP ®) officially launched its next...

September 14th, 2021Study Description Go to Brief Summary: This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to...

September 9th, 2021Last Notice Chondrosarcoma CS Foundation, Inc. Virtual Dialogue 3: Taking Charge of Your Care Third International Virtual Dialogue (VIA Zoom) Tuesday, September 14, 2021 7:30PM – 9:00PM (Eastern Standard Time / New York) This Event is Free to...

August 31st, 2021The Chondrosarcoma Foundation is hosting its first fundraising event to bring awareness to Chondrosarcoma: a rare bone and soft tissue cancer. Where: The comfort of your own neighborhood! When: anytime between October 3rd-9th TO...

August 11th, 2021 https://www.eventbrite.com/e/steppin-for-a-cause-tickets-166736518415

August 10th, 2021The Chondrosarcoma CS Foundation, Inc. will host its Third International Forum / Virtual Dialogue featuring a panel of Chondrosarcoma Survivors and prominent experts to examine new technologies, medications, and clinical trials, as well as providing...

August 9th, 2021Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist For more information: Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human...

August 1st, 2021 Did you know... Research initiated by the Bone Cancer Research Trust discovered that navigation guided surgery improves 5-year chondrosarcoma-specific survival from 53% to 76%! Read about this life-saving breakthrough and many more in our new...